Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1

miR-375 inhibits cancer stem cell phenotype and tamoxifen resistance by degrading HOXB3 in human ER-positive breast cancer

(2017) Hui Fu et al.   ONCOLOGY REPORTS

CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer

(2016) Shawn F. Johnson et al.   Cell Reports

Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer

(2015) S. E. Wardell et al.   CLINICAL CANCER RESEARCH

Function of BRCA1 in the DNA Damage Response Is Mediated by ADP-Ribosylation

(2013) Mo Li et al.   CANCER CELL

Sox2 promotes tamoxifen resistance in breast cancer cells

(2013) Marco Piva et al.   EMBO Molecular Medicine

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

(2013)   LANCET

The BRCA1/BARD1-Interacting Protein OLA1 Functions in Centrosome Regulation

(2013) Ayako Matsuzawa et al.   MOLECULAR CELL

Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan

(2012) Stephen Hiscox et al.   BMC CANCER

Hedgehog Signaling Is a Novel Therapeutic Target in Tamoxifen-Resistant Breast Cancer Aberrantly Activated by PI3K/AKT Pathway

(2012) B. Ramaswamy et al.   CANCER RESEARCH

A DNA-Damage Selective Role for BRCA1 E3 Ligase in Claspin Ubiquitylation, CHK1 Activation, and DNA Repair

(2012) Ko Sato et al.   CURRENT BIOLOGY

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer

(2012) A Ward et al.   ONCOGENE

PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition

(2012) Yasir H. Ibrahim et al.   Cancer Discovery

A Kinome-Wide Screen Identifies the Insulin/IGF-I Receptor Pathway as a Mechanism of Escape from Hormone Dependence in Breast Cancer

(2011) E. M. Fox et al.   CANCER RESEARCH

Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer

(2011) C. Thangavel et al.   ENDOCRINE-RELATED CANCER

Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition

(2011) Neil Johnson et al.   NATURE MEDICINE

Targeting the Phosphoinositide-3 (PI3) Kinase Pathway in Breast Cancer

(2011) J. Baselga   ONCOLOGIST

Nuclear phosphoinositide 3-kinase   controls double-strand break DNA repair

(2010) A. Kumar et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cdk1 Participates in BRCA1-Dependent S Phase Checkpoint Control in Response to DNA Damage

(2009) Neil Johnson et al.   MOLECULAR CELL

Cyclin D1 Expression in Breast Cancer Patients Receiving Adjuvant Tamoxifen-Based Therapy

(2008) M. Rudas et al.   CLINICAL CANCER RESEARCH

Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer

(2008) D. Meijer et al.   ENDOCRINE-RELATED CANCER